Genmab reported 201M in Selling and Administration Expenses for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agios Pharmaceuticals AGIO:US $ 33.55M 6.23M
Alexion Pharmaceuticals ALXN:US $ 342.9M 101.5M
Amarin AMRN:US 105.8M 11.02M
Amgen AMGN:US $ 1.25B 519M
Bayer BAYN:GR 3.52B 30M
Biomarin Pharmaceutical BMRN:US $ 184.16M 9.84M
Bluebird Bio BLUE:US $ 86.87M 9.9M
Exelixis EXEL:US $ 102.35M 19.91M
Fresenius Medical Care FME:GR 712M 167.37M
Galapagos GLPG:NA 45M 6.62M
Genmab GEN:DC 201M 30M
GlaxoSmithKline GSK:LN 2.5B 183M
GN Store Nord GN:DC 1.13B 27M
GRIFOLS GRF:SM 257.14M 4.21M
H. Lundbeck A/S LUN:DC 1.5B 432M
Hikma Pharmaceutical HIK:LN 235M 6M
Immunogen IMGN:US $ 10.21M 471K
Insmed INSM:US $ 51.55M 4.47M
Merck MRK:GR 1.28B 163M
Novartis NOVN:VX 3.52B 388M
Regeneron Pharmaceuticals REGN:US $ 405.6M 102.1M
Seattle Genetics SGEN:US $ 159.84M 1.48M
William Demant Holding WDH:DC 3.98B 132M